Uterine leiomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Uterine leiomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Post-Operative Chemotherapy with Doxorubicin and Trabectedin for Patients with High-Risk Localized Uterine Leiomyosarcoma https://clinicaltrials.eu/trial/study-on-post-operative-chemotherapy-with-doxorubicin-and-trabectedin-for-patients-with-high-risk-localized-uterine-leiomyosarcoma/ Wed, 29 Apr 2026 15:01:24 +0000 https://clinicaltrials.eu/trial/study-on-post-operative-chemotherapy-with-doxorubicin-and-trabectedin-for-patients-with-high-risk-localized-uterine-leiomyosarcoma/ This clinical trial is focused on studying a type of cancer called uterine leiomyosarcoma, which is a rare cancer that occurs in the smooth muscle tissue of the uterus. The study is specifically looking at cases where the cancer has been surgically removed but is considered high-risk for coming back. The purpose of the study is to see if adding chemotherapy after surgery can help prevent the cancer from returning. The chemotherapy treatment being tested includes two medications: doxorubicin and trabectedin. These medications are given as a solution through an infusion, which means they are delivered directly into the bloodstream through a vein.

Participants in the study will be randomly assigned to one of two groups. One group will receive the chemotherapy treatment with doxorubicin and trabectedin, while the other group will be observed without additional treatment. The study will last for a period of time, during which participants will receive up to four cycles of chemotherapy if they are in the treatment group. The goal is to determine if the chemotherapy helps improve the time patients remain free from cancer recurrence compared to those who do not receive the additional treatment.

Throughout the study, participants will be monitored for any side effects from the treatment, as well as their overall health and quality of life. The study aims to provide valuable information on whether this chemotherapy combination can be beneficial for patients with high-risk uterine leiomyosarcoma after surgery. This research could potentially lead to improved treatment options for patients facing this challenging condition.

]]> Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]>